Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
BRIEF-Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study Sept 8 (Reuters) - Inhibrx Biosciences Inc INBX.O:
INHIBRX'S INBRX-106 NEARLY DOUBLES RESPONSE RATE AND ACHIEVES INTERIM MEDIAN PFS OF 9.6 MONTHS IN PHASE 2 HNSCC STUDY
INHIBRX BIOSCIENCES - INBRX-106 PLUS PEMBROLIZUMAB ACHIEVES 48.3% CORR AND 72.4% SIX-MONTH PFS RATE
INHIBRX BIOSCIENCES - TO EXPAND PHASE 2 STUDY BY 50 HPV+ PATIENTS
INHIBRX BIOSCIENCES INC: ALSO PLANS TO EXPLORE POTENTIAL OF INBRX-106 IN COMBINATION WITH THERAPEUTIC CANCER VACCINES
INHIBRX BIOSCIENCES INC: EVALUATING POTENTIAL OF INBRX-106 IN OTHER HIGHLY IMMUNOGENIC TUMOR TYPES
INHIBRX BIOSCIENCES: CURRENTLY CONDUCTING PHASE 1/2 STUDY OF INBRX-106 IN PERIOPERATIVE SETTING OF NSCLC, WITH INITIAL RESULTS TARGETED BY MID-2027
Source text: ID:nPn6J28q4a
Further company coverage: INBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibrx Biosciences
See all newsInhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study (updated)
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
NASDAQ RESUMED AT 08:00 AM
Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM